310 related articles for article (PubMed ID: 33548284)
1. The therapeutic potential of renin-angiotensin system inhibitors in the treatment of pancreatic cancer.
Khoshghamat N; Jafari N; Toloue-Pouya V; Azami S; Mirnourbakhsh SH; Khazaei M; Ferns GA; Rajabian M; Avan A
Life Sci; 2021 Apr; 270():119118. PubMed ID: 33548284
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers as Potential Therapeutic Options for Pancreatic Cancer.
Asgharzadeh F; Geraylow KR; Khazaei M; Nassiri M; Hassanian SM; Ferns GA; Avan A
Curr Cancer Drug Targets; 2022; 22(10):785-795. PubMed ID: 35585824
[TBL] [Abstract][Full Text] [Related]
3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
4. Recent changes in the landscape of combination RAS blockade.
Epstein BJ; Smith SM; Choksi R
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
[TBL] [Abstract][Full Text] [Related]
5. Renin-angiotensin system blocking drugs.
Robles NR; Cerezo I; Hernandez-Gallego R
J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):14-33. PubMed ID: 24038019
[TBL] [Abstract][Full Text] [Related]
6. Should ACE inhibitors and ARBs be used in combination in children?
Stotter BR; Ferguson MA
Pediatr Nephrol; 2019 Sep; 34(9):1521-1532. PubMed ID: 30112656
[TBL] [Abstract][Full Text] [Related]
7. Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?
Gerc V; Buksa M; Loza V; Kulic M
Med Arh; 2009; 63(6):343-9. PubMed ID: 20380117
[TBL] [Abstract][Full Text] [Related]
8. Reducing cardiorenal risk through combination therapy with a direct renin inhibitor.
Rastogi A; Rashid M; Wright RF
J Clin Hypertens (Greenwich); 2011 Nov; 13(11):848-55. PubMed ID: 22051431
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin receptor blockers: evidence for preserving target organs.
Carson P; Giles T; Higginbotham M; Hollenberg N; Kannel W; Siragy HM
Clin Cardiol; 2001 Mar; 24(3):183-90. PubMed ID: 11288962
[TBL] [Abstract][Full Text] [Related]
10. Development of inhibitors of the aspartyl protease renin for the treatment of hypertension.
Scott BB; McGeehan GM; Harrison RK
Curr Protein Pept Sci; 2006 Jun; 7(3):241-54. PubMed ID: 16787263
[TBL] [Abstract][Full Text] [Related]
11. Renin inhibition--benefit beyond hypertension control.
Kher V
J Assoc Physicians India; 2009 Jul; 57():518-20, 525. PubMed ID: 20329413
[TBL] [Abstract][Full Text] [Related]
12. [The future of renin inhibition].
Uresin AY; Baran E
Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
[TBL] [Abstract][Full Text] [Related]
13. Systematic review: Renin-angiotensin system inhibitors in chemoprevention of hepatocellular carcinoma.
Barone M; Viggiani MT; Losurdo G; Principi M; Leo AD
World J Gastroenterol; 2019 May; 25(20):2524-2538. PubMed ID: 31171895
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?
Messerli FH; Bangalore S; Bavishi C; Rimoldi SF
J Am Coll Cardiol; 2018 Apr; 71(13):1474-1482. PubMed ID: 29598869
[TBL] [Abstract][Full Text] [Related]
15. The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review.
Ferrari R; Boersma E
Expert Rev Cardiovasc Ther; 2013 Jun; 11(6):705-17. PubMed ID: 23750680
[TBL] [Abstract][Full Text] [Related]
16. Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: A number-needed-to-treat analysis.
Brugts JJ; van Vark L; Akkerhuis M; Bertrand M; Fox K; Mourad JJ; Boersma E
Int J Cardiol; 2015 Feb; 181():425-9. PubMed ID: 25569271
[TBL] [Abstract][Full Text] [Related]
17. The Potential Therapeutic Value of Renin-Angiotensin System Inhibitors in the Treatment of Colorectal Cancer.
Tabatabai E; Khazaei M; Parizadeh MR; Nouri M; Hassanian SM; Ferns GA; Rahmati M; Avan A
Curr Pharm Des; 2022; 28(1):71-76. PubMed ID: 34635038
[TBL] [Abstract][Full Text] [Related]
18. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
Weber MA
J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125
[TBL] [Abstract][Full Text] [Related]
19. New approaches to blockade of the renin-angiotensin-aldosterone system: evidence from randomized controlled trials (RCTs) of angiotensin-converting enzyme inhibitors and angiotensin II-receptor blockers--questions remain unsolved.
Ueda S
J Pharmacol Sci; 2010; 113(4):292-5. PubMed ID: 20675956
[TBL] [Abstract][Full Text] [Related]
20. The benefit of angiotensin AT1 receptor blockers for early treatment of hypertensive patients.
Trimarco B; Santoro C; Pepe M; Galderisi M
Intern Emerg Med; 2017 Dec; 12(8):1093-1099. PubMed ID: 28770426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
